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The hereditary disorders of peripheral nerve form one of the most common groups of human genetic diseases,
collectively called Charcot-Marie-Tooth (CMT) neuropathy. Using linkage analysis we have identified a new locus
for a form of CMT that we have called “dominant intermediate CMT” (DI-CMT). A genomewide screen using
383 microsatellite markers showed strong linkage to the short arm of chromosome 19 (maximum LOD score 4.3,
with a recombination fraction (v) of 0, at D19S221 and maximum LOD score 5.28, , at D19S226). Haplotypevp 0
analysis performed with 14 additional markers placed the DI-CMT locus within a 16.8-cM region flanked by the
markers D19S586 and D19S546. Multipoint linkage analysis suggested the most likely location at D19S226 (max-
imum multipoint LOD score 6.77), within a 10-cM confidence interval. This study establishes the presence of a
locus for DI-CMT on chromosome 19p12-p13.2.
Charcot-Marie-Tooth (CMT) neuropathy, otherwise
known as “hereditary motor and sensory neuropathy”
(HMSN), is one of the most common groups of hu-
man hereditary disorders. The CMT syndrome includes
many hereditary disorders of peripheral nerve affecting
both motor and sensory neurons. The CMT phenotype
is characterized by progressive weakness and atrophy of
distal muscles, high arched feet (pes cavus), and loss of
deep-tendon reflexes. CMT can be divided into two sub-
groups: CMT I, disorders of Schwann cells with nerve-
conduction slowing, and CMT II, disorders of the distal
portions of neurons, also known as the “axonal neu-
ropathies” (Dyck and Lambert 1968). The known causes
of CMT I are a 1.5-mb DNA duplication on chromo-
some 17p11.2-p12 (CMT1A [MIM 118220]) (Lupski et
al. 1991; Raeymaekers et al. 1991) causing trisomy of
the peripheral myelin protein 22 gene (PMP22 [Gen-
Bank accession number L03203]) (Matsunami et al.
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1992; Patel et al. 1992; Timmerman et al. 1992; Val-
entijn et al. 1992b), point mutations in connexin 32
(Cx32/GJB1 [GenBank accession number XM_047682]
and CMT1X [MIM 302800]; Bergoffen et al. 1993),
point mutations of two myelin genes, peripheral my-
elin protein 22 (PMP22 in CMT1A; Valentijn et al.
1992a), myelin protein zero (MPZ/Po [GenBank acces-
sion numbers D10537 and D90501] in CMT1B [MIM
118200]; Hayasaka et al. 1993), and mutations in the
transcription factor (EGR2 [GenBank accession num-
ber AF139463]; Warner et al. 1998). Motor-nerve con-
duction in the most common form of CMT type I
(CMT1A) is typically ∼20 m/s and is usually !40 m/s
(Nicholson 1991). Males with the next-most-common
form (CMT1X) have median conduction velocities !45
m/s (Nicholson and Nash 1993).
In CMT II, median nerve-conduction velocity is usu-
ally 138 m/s (Harding and Thomas 1980) or 145 m/s
(Dyck and Lambert 1968). Nerve conduction is not
slowed until axonal degeneration occurs; then, as large
fibers are lost, mild slowing of conduction occurs. Even-
tually, when all fibers are lost, no responses are obtained.
We have used the value of 45 m/s to define the cutoff
between CMT I and CMT II, since this value is in agree-
ment with both Dyck and Lambert’s definition and with
our results for CMT1A and CMT1X males.
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Table 1
Two-Point LOD Scores between the Dominant Intermediate CMT
Locus and Microsatellite Markers on Chromosome 19p
MARKER
LOD AT v p
.00 .01 .05 .10 .20 .30 .40
D19S912 3.46 1.59 .40 .05 .06 .02 .08
D19S922 7.50 3.35 1.41 .74 .39 .40 .27
D19S586 .23 3.19 3.54 3.38 2.69 1.75 .71
D19S584 4.40 4.32 3.97 3.51 2.53 1.48 .47
D19S1165 4.56 4.48 4.18 3.78 2.89 1.88 .81
D19S221 4.30 4.20 3.83 3.34 2.29 1.20 .27
D19S558 5.59 5.51 5.18 4.74 3.75 2.60 1.29
D19S930 2.83 2.77 2.54 2.24 1.60 .94 .34
D19S226 5.28 5.20 4.86 4.41 3.44 2.34 1.13
D19S244 3.59 3.52 3.20 2.81 2.00 1.20 .47
D19S199 2.80 2.75 2.52 2.21 1.58 .92 .33
D19S410 3.81 3.74 3.44 3.05 2.21 1.32 .46
D19S546 8.59 1.92 .17 .47 .81 .70 .40
D19S568 5.61 1.67 .85 .51 .25 .13 .04
D19S875 3.74 .54 .54 .87 .78 .32 .11
D19S882 7.94 1.33 .06 .56 .81 .67 .35
Figure 1 Genetic map (sex averaged) of chromosome 19 markers
used in this study. The genetic distances were obtained from the Marsh-
field map. Loci that appear on the same line map to the same genetic
location. The order of these markers was obtained from the chro-
mosome 19 p-arm metric physical map. Markers defining the DI-CMT
genetic interval are shown in boldface.
The only known mutations causing CMT II are mu-
tations in the neurofilament light gene (NEFL [GenBank
accession number X05608]) in CMT2E (MIM 162280;
Mersiyanova et al. 2000), the MPZ/Po (Marrosu et al.
1998; Senderek et al. 2000), and the microtubule motor
KIF1Bb gene (KIF1Bb [GenBank accession number
AB023656]) in CMT2A (MIM 118210; Zhao et al.
2001).
We have used the term “intermediate conduction ve-
locity” to describe CMT families with nerve-conduction
velocities, in different affected individuals, that overlap
the division between CMT I and CMT II (45 m/s). A
functional definition is to use the term for families with
a range of nerve-conduction velocities, including both
the CMT I and CMT II ranges. There has been contro-
versy about whether an intermediate form of CMT ex-
ists; however, families of this type have been reported
(Salisachs 1974; Davis et al. 1978). An Italian family
has been described with a dominantly inherited form of
CMT with intermediate median motor-nerve–conduc-
tion velocities (Rossi et al. 1985; Villanova et al. 1998).
Two MPZ/Po mutations are associated with interme-
diate conduction velocities (De Jonghe et al. 1999; Mas-
taglia et al. 1999). We have identified a large family (DI-
CMT310) with conduction velocities ranging from 24
to 54 m/s. The sural-nerve biopsy in this family shows
axonal degeneration, loss of large-diameter fibers, rare
segmental demyelination, and remyelination with onion
bulb formation, as in the family reported by Villanova
et al. (1998).
Genomic DNA was extracted from peripheral blood
leukocytes, using standard techniques. A genomewide
linkage screen was performed at the Australian Genome
Research Facility, using 383 microsatellite markers from
the ABI Prism Linkage Mapping Set Version 2 (PE Ap-
plied Biosystems). DI-CMT was assumed to be an au-
tosomal dominant trait with a penetrance of 90% by
age 20 years. The disease allele had a frequency of .0001,
with a phenocopy rate of 0. Male and female recom-
bination rates were considered to be equal. Marker allele
frequencies were set at 1/n, where n is the number of
alleles observed. When marker allele frequencies were
varied using available population data, this had little or
no effect on the LOD score results. Information on ad-
ditional markers to confirm and refine the interval were
accessed through the Genome Database, and samples
were PCR amplified as described elsewhere (Nicholson
et al. 1996). Linkage analysis was performed using the
MLINK and Linkmap programs of the Linkage package
(V5.1) (Lathrop et al. 1984) in the Fastlink implemen-
tation (version 4.1p; Cottingham et al. 1993). Both two-
point and multipoint analyses were performed. For mul-
tipoint analysis, the genetic distances between loci were
obtained from the Marshfield sex-averaged linkage map
and were converted to recombination fractions using
Haldane’s mapping function. The method wasZ  1max
used to determine the 95% confidence limits and support
interval for the DI-CMT locus (Conneally et al. 1985).
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Figure 2 Haplotype analysis of markers from chromosome 19p12-p13.2 in family (DI-CMT310) with autosomal dominant intermediate
CMT. The haplotype segregating with the disease is boxed. The markers are presented in order from telomere (top) to centromere (bottom).
Blackened symbols denote affected individuals, and unblackened symbols denote unaffected individuals. Individuals are numbered consecutively
in each generation, from left to right. Individuals IV-1 and IV-12 define the centromeric boundary of the disease at D19S546, whereas individual
IV-16 defines the telomeric boundary at D19S586.
Haplotypes were assigned on the basis of the minimi-
zation of intermarker recombination.
Prior to performance of a genome screen on family
DI-CMT310, all known CMT I (CMT1A, CMT1B) and
CMT II (CMT2A, CMT2B [MIM 600882], CMT2C
[MIM 606071], CMT2D [MIM 601472], CMT2E) loci
were excluded by either linkage analysis or mutation
screening (data not shown). Simulation studies indicated
that the family could independently demonstrate linkage
(LOD score 1 3.0) and was capable of excluding 11.6
cM on either side of an unlinked marker (data not
shown). A genome screen was subsequently undertaken
using markers spaced, on average, at 10-cM intervals.
Linkage was established to chromosome 19p12-p13.2
when significant LOD scores were obtained with the
consecutive markers D19S221 and D19S226 (table 1).
No other markers analyzed from the genome screen gave
a LOD score 3.0. Fourteen additional markers were
then tested in the family. The results of the two-point
analysis between the disease phenotype and the addi-
tional marker loci are shown (table 1). Extended haplo-
types of individuals were constructed according to the
order of both the Marshfield genetic map and the chro-
mosome 19 p-arm metric physical map (fig. 1). Haplo-
type analysis detected no recombination between DI-
CMT and seven closely linked markers (D19S584,
D19S1165, D19S221, D19S558, D19S226, D19S244,
and D19S410). The markers D19S930 and D19S199 did
not generate a LOD score of 3.0, but the alleles from
these markers formed part of the disease haplotype seg-
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Figure 3 Multipoint localization of dominant intermediate
CMT. Genetic location (distance, in cM, from the telomere of chro-
mosome 19p) is plotted against the multipoint LOD score. Markers
used in the multipoint analysis are shown. A maximum multipoint
LOD score of 6.77 was obtained for D19S226 at 42.28 cM. The
markers D19S586 and D19S199 flank the 10-cM confidence interval.
regating in this family (fig. 2). On the basis of the anal-
ysis, the proximal recombination site is between
D19S546 and D19S410, as observed in two affected
individuals (IV-1 and IV-12), and the distal recombi-
nation site is between D19S586 and D19S584 as ob-
served in a single affected family member (IV-16). These
results suggest the localization of DI-CMT to be within
a 16.8-cM interval between D19S586 and D19S546.
Multipoint linkage analysis was performed using the
markers D19S586, D19S584, D19S558, D19S226,
D19S199, D19S410, and D19S546. The most likely lo-
cation for DI-CMT is D19S226, with a maximum mul-
tipoint LOD score of . By use of theZp 6.77 Z max
method, the inferred location of the DI-CMT locus1
has been narrowed to within a 10-cM confidence inter-
val (8.2 cM telomeric and 1.8 cM centromeric to
D19S226; see fig. 3).
Although the 16.8-cM interval containing the DI-
CMT locus is too large for practical positional cloning,
the region has been almost completely sequenced. Re-
finement of the critical interval, however, will be required
before mutation screening of expressed sequences within
the region is undertaken. The chromosome 19 p-arm
metric physical map (Lawrence Livermore Laboratory)
has listed 53 genes that have been mapped on a cosmid
contig in the interval between D19S586 and D19S546.
Several other diseases and associated genes have been
mapped to the same region as DI-CMT. They include
cerebral autosomal dominant arteriopathy with subcor-
tical infarcts and leukoencephalopathy (NOTCH3; Jou-
tel et al. 1996), episodic ataxia and familial hemiplegic
migraine (CACNLA1A4; Jodice et al. 1997), and, more
recently, a locus for autosomal dominant polycystic liver
disease was mapped to this region (Reynolds et al. 2000).
DI-CMT shares clinical features with CMT I and CMT
II. Genes identified for CMT type I and II could give clues
to positional candidate genes for DI-CMT. Currently, 30
genetic loci have been identified for distinct forms of
CMT; however, only 10 genes have been identified (Meu-
leman et al. 2000). Genes associated with recessive pe-
ripheral neuropathies include the gene encoding the phos-
phatase myotubularin-related protein 2 (MTMR2 [Gen-
Bank accession number NM_003912]; Bolino et al.
2000), a protein involved with cell-cycle regulation and
signal transduction (NDRG1 [GenBank accession num-
ber XM_051273]; Kalaydjieva et al. 2001), a receptor for
a neurotrophic factor (NTRK1/TrkA [GenBank accession
number XM_043533]; Bodzioch et al. 2001; Houlden et
al. 2001), and a protein (periaxin) associated with mye-
linating Schwann cells (PRX [GenBank accession number
XM_047407]; Guilbot et al. 2001). The genes involved
with dominant CMT I and CMT II represent a spectrum
of proteins with diverse functions ranging from a struc-
tural protein (PMP22), an adhesion molecule (MPZ/Po),
a transcription factor (EGR2), a mitochondrial transport
protein (KIF1Bb), and a cytoskeletal protein (NEFL). All
these genes are expressed in peripheral nerve and play a
role in Schwann cell biology and myelination (PMP22
and MPZ/Po), axonal structure (NEFL), axonal trans-
port (KIF1Bb), and differentiation of the myelinating
Schwann cell (EGR2). Possible candidates for DI-CMT,
on the basis of their expression profiles in peripheral
nerve and spinal cord, respectively, include the growth
differentiation factor 1 gene (GDF-1; Lee 1991) and
the brain-specific membrane anchored protein gene
(BSMAP; Elson et al. 1999). BSMAP was localized to
the DI-CMT interval, according to the Unified Database
for Human Genome Mapping (Weizmann Institute). In
addition to these two genes, the protein kinase C sub-
strate 80K-H (PRKCSH) could also be a positional can-
didate, because of its potential role in neuronal signal
transduction (Ophoff et al. 1996). Screening of these
genes is currently being performed. The remaining genes
in the region have reported tissue expression or possible
functions that eliminate their role as strong positional
candidates for this disease.
Another possible clue to mechanisms involved in dom-
inant intermediate CMT is given by the Cx32/GJB1 gene
mutated in CMT1X. CMT1X has a mixed axonal and
demyelinating appearance on biopsy, and affected males
have slowing of nerve-conduction velocities due to de-
myelination. Connexin 32 is a protein that forms channels
between myelin lamellae and the myelin/axonal interface.
Mutations in connexin 32 disrupt the connexin channel
between myelin lamellae and axons, resulting in degen-
eration of both myelin and axons. Dominant intermediate
CMT could be caused by a gene with a similar function.
Linkage studies localizing DI-CMT to 19p12-13.2
have shown that dominant intermediate CMT exists as
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a separate genetic entity. Because the disease shows both
axonal and demyelinating features, identification of the
gene involved with this disorder may elucidate axonal
and myelin interactions. Such interactions are relevant
to understanding secondary axonal degeneration, a di-
rect cause of disability in both axonal and demyelinating
neuropathies.
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